Prosecution Insights
Last updated: November 20, 2026

Padmaja S Rao, USPTO Patent Examiner

Listed by the USPTO as RAO, PADMAJA S

Tech Center 1600 • Art Units: 1627

This examiner grants 71% of resolved cases

Analysis

RAO, PADMAJA S is assigned to Tech Center 1600 and Art Unit 1627. The profile covers 161 resolved cases, with an allowance rate of 70.8% and a median of 1114 days to allowance. The interview lift is 36.5%, indicating a meaningful measured association between interviews and allowance outcomes.

Enyo Pharma, The Regents of the University of California, and Massachusetts Institute of Technology are the leading companies or institutions represented. The leading firms are SALIWANCHIK, LLOYD & EISENSCHENK, BakerHostetler, and BALLARD SPAHR LLP. Practitioners may wish to pair focused claim work with interview preparation, while accounting for the median prosecution timeline.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

70.8%
Allow Rate
+10.8% vs TC avg
208
Total Applications
+36.5%
Interview Lift
1114
Avg Prosecution Days
Based on 161 resolved cases, 2023–2026

Rejection Statute Breakdown

3.7%
§101 Eligibility
17.0%
§102 Novelty
32.1%
§103 Obviousness
26.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18551428 Compositions and Methods for Inhibiting and Treating Viral Infections Non-Final OA The Regents of the University of California
18065348 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION Non-Final OA Massachusetts Institute of Technology
18251079 MODULATORS OF THE INTEGRATED STRESS PATHWAY Non-Final OA AbbVie Inc.
18699188 PYRAZOLE COMPOUNDS AND USES THEREOF Non-Final OA ALCON INC.
17291055 COMPOSITIONS AND METHODS USING A COMBINATION OF CURCUMIN AND AN OMEGA-3 FATTY ACID FOR CELLULAR ENERGY Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
17770686 USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION Final Rejection SK BIOPHARMACEUTICALS CO., LTD.
17791110 A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18043163 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF Non-Final OA THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS
18566176 SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE Final Rejection VERTEX PHARMACEUTICALS INCORPORATED
18692018 PROCESS FOR PREPARING 5-FLUORO-4-IMINO-3-METHYL-1-(TOLUENE-4- SULFONYL)-3,4-DIHYDRO-1H-PYRIMIDIN-2-ONE Non-Final OA Adama Makhteshim Ltd.
18351359 INJECTABLE METHODS TO TREAT DEFICIENCIES IN GLUTATHIONE METABOLISM AND HOMOCYSTINURIA Non-Final OA Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Padmaja S Rao's allowance rate?

70.8% of resolved applications examined by Padmaja S Rao were allowed (161 resolved cases), compared with 35.4% across Art Unit 1627 over the last five years.

Does an interview help with examiner Padmaja S Rao?

This examiner's interview lift is +36.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Padmaja S Rao take to allow a patent?

Applications allowed by Padmaja S Rao took 1,114 days on average from filing to allowance.

Which art unit does examiner Padmaja S Rao work in?

Padmaja S Rao examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month